|Email Newsletters from Pharmaceutical Technology and Pharmaceutical Technology Europe|
News from Europe's pharmaceutical manufacturing industry coupled with upcoming events, and exclusive articles and interviews from industry experts.
Industry Briefs: Apr. 16, 2012
AMRI and Biota have agreed to develop and manufacture the influenza antiviral CS8958 (laninamivir), a second-generation, long-acting neuraminidase inhibitor. Read More
Evans Analytical Group (EAG) has acquired PTRL West and PTRL Europe. Read More
Nascent and Catalent Pharma Solutions have formed a product-development agreement for a Nascent antibody drug candidate. Read More
Pharmatek has added to its liquid encapsulation capabilities. Read More
Q Laboratories has completed construction on its 5000-ft2 microbiology research and development laboratory.
Shire has agreed to acquire Pervasis Therapeutics and related endothelial cell technology. Read More
Vanda Pharmaceuticals has acquired the rights to an NK-1 receptor antagonist from Eli Lilly. Read More
Hospira has named John B. Elliot senior vice-president of operations. Read More
Penn Pharma has appointed Jerome Detreille as senior director of new business development. Read More
Michael A. Griffith has been appointed to Repligen’s board of directors. Read More